Lipid-lowering therapies show promising results for patients with HoFH in real-world setting

The availability and utilization of novel lipid-lowering therapies (LLTs) have led to significant advancements in the clinical management of homozygous familial hypercholesterolaemia (HoFH), according to a study. The study highlights that through a combination of conventional and cutting-edge LLTs, LDL-C control has greatly improved, resulting in a marked reduction in...